Name-brand medications driving spike in U.S. drug spending

Name-brand medications driving spike in U.S. drug spending

(HealthDay)—Rising drug spending in the United States is being fueled by expensive name-brand prescription medicines, a new study shows.

"Total prescription drug spending increased 10 percent annually since 2010," and 82 percent of were for cheaper, , according to the Blue Cross Blue Shield study, NBC News reported. But the study also showed that expensive "branded prescription drugs accounted for only 17 percent of total prescriptions filled, but 79 percent of total prescription drug spending [$79.5 billion]."

"More expensive branded prescription drug spending is up 4 percent since 2016," and costs "for single-source drugs with no generic alternatives increased at more than double the rate of average annual drug spending," according to the study.

The biggest costs were from three rheumatoid arthritis drugs—Humira, Remicade, and Enbrel—a quick-acting insulin called Novolog, and Neulasta, an immune system-strengthening treatment for cancer patients, NBC News reported.

More information: NBC News Article
Blue Cross Blue Shield Report

Copyright © 2018 HealthDay. All rights reserved.

Citation: Name-brand medications driving spike in U.S. drug spending (2018, November 16) retrieved 22 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Spending on prescription meds up about 5 percent in 2015


Feedback to editors